Capecitabine Induced Hand And Foot Syndrome

• Status: Not yet recruiting
• Trial end date: 2023-11-01
• Target enrollment: 0
• Participant gender: Female

Summary

The aim of the study is to evaluate the efficacy of using combination of Urea-based cream (CARBAMIDE®) and topical diclofenac (VOLTAREN®) Emulgel 1% for improving the incidence of Hand-foot syndrome in histologically proven breast cancer Egyptian patients receiving single agent chemotherapy Capecitabine (XELODA ®) and Its effect on improving patients' quality of life.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: German University in Cairo
• Collaborator: Cairo University
• Treatments: Diclofenac

Criteria

Inclusion Criteria:

1. Adults aged 18 years and above.

2. Females.

3. Histologically proven breast cancer patients receiving Capecitabine (XELODA ®) chemotherapy.

4. life expectancy greater than 18 weeks.

Exclusion Criteria:

1. Hypersensitivity to diclofenac, aspirin or other non-steroidal anti-inflammatory drugs (NSAIDS).

2. History of Urticaria.

3. History of acute rhinitis

4. Asthmatic Patients.